Making data on essential pharmacogenes available for every patient everywhere: The medicine safety code initiative

Pharmacogenomics

Volumn 14, Issue 13, 2013, Pages 1529-1531

  Samwald, Matthias ^a   Freimuth, Robert R ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MAYO CLINIC   (United States)

Author keywords

biomedical informatics; clinical decision support systems; healthcare systems; pharmacogenetics

Indexed keywords

CLINICAL PRACTICE; COMPUTER SYSTEM; DRUG COST; DRUG DATABASE; DRUG INFORMATION; DRUG SAFETY; HEALTH CARE AVAILABILITY; HUMAN; PATIENT CARE; PHARMACOGENETICS; REVIEW; RISK BENEFIT ANALYSIS; TOTAL QUALITY MANAGEMENT;

DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACOGENETICS; SAFETY;

EID: 84885409171     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.121     Document Type: Review

References (3)

1. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates: Results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
2. Samwald M, Coulet A, Huerga I et al. Semantically enabling pharmacogenomic data for the realization of personalized medicine. Pharmacogenomics 13(2), 201-212 (2012).
3. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: Development of a cost-effective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther. 92(4), 437-439 (2012).